The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Lubnin A.Yu.

Moscow Regional Research Institute of Obstetrics and Gynecology, Ministry of Health of the Moscow Region, Moscow, Russia, N.N. Burdenko Research Institute of Neurosurgery, Moscow, Russia, Department of Obstetrics and Gynecology, M.F. Vladimirsky Moscow Regional Research Clinical Institute, Moscow, Russia

The use of activated recombinant factor VII in neurosurgery

Authors:

Lubnin A.Yu.

More about the authors

Journal: Burdenko's Journal of Neurosurgery. 2018;82(2): 112‑119

DOI: 10.17116/oftalma2018822112-119

Read: 2163 times

Contact the author
Table of contents

THE USE OF ACTIVATED RECOMBINANT FACTOR VII IN NEUROSURGERY
THE USE OF ACTIVATED RECOMBINANT FACTOR VII IN NEUROSURGERY

To cite this article:

Lubnin AYu. The use of activated recombinant factor VII in neurosurgery. Burdenko's Journal of Neurosurgery. 2018;82(2):112‑119. (In Russ., In Engl.)
https://doi.org/10.17116/oftalma2018822112-119

Подписка 2025 Журнал «Вопросы нейрохирургии» имени Н.Н. Бурденко (Burdenko's Journal of Neurosurgery)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Authors:

Lubnin A.Yu.

Moscow Regional Research Institute of Obstetrics and Gynecology, Ministry of Health of the Moscow Region, Moscow, Russia, N.N. Burdenko Research Institute of Neurosurgery, Moscow, Russia, Department of Obstetrics and Gynecology, M.F. Vladimirsky Moscow Regional Research Clinical Institute, Moscow, Russia

Close metadata

References:

  1. Hunt DJ. Bleeding in surgical patients. In: Murphy MF, Pamphilon DH. (eds.). Practical transfusion medicine. 2001. Blackwell Sci. Oxford etc.;77-86.
  2. Counts RB. Transfusion medicine in the surgical patient. In: Spies BD, Counts RB, Gould SA. (eds.). Perioperative transfusion medicine. Williams&Wilkins. Baltimore etc.;1998;15-26.
  3. Lubnin AYu, Gromova VV, Hansen E. Blood reinfusion in surgery. 2013. Tver: Triada;431. (In Russ.)
  4. Perez-Cruet MJ, Sawaya R. Transfusion issues in neurosurgery. In: Spies BD, Counts RB, Gould SA. (eds.). Perioperative transfusion medicine. Williams&Wilkins. Baltimore etc. 1998;553-570.
  5. Kalfas IH, Little JR. Postoperative hemorrhage: a survey of 4992 intracranial procedures. Neurosurgery. 1988;23:343-347.
  6. Palmer J, Sparrow O, Iannotti F. Postoperative hematoma: a 5-year survey and identification of avoidable risk factors. Neurosurgery. 1994;35:1061-1065.
  7. Gerlach R, Raabe A, Scharrer I. Post-operative hematoma after surgery for intracranial meningiomas: causes, avoidable risk factors and clinical outcome. Neurol Res. 2004;26:61-66. https://doi.org/10.1179/016164104773026543
  8. Boshkov LK. Platelet transfusions. In: Goodnight SH, Hathaway WE. (eds.). Disorders of hemostasis & thrombosis. A clinical guide. 2nd ed. McGraw-Hill. NY. 2001;489-494.
  9. Boshkov LK Plasma. In: Goodnight SH, Hathaway WE. (eds.). Disorders of hemostasis & thrombosis. A clinical guide. 2nd ed. McGraw-Hill. NY. 2001;495-500.
  10. Boshkov LK. Cryoprecipitate. In: Goodnight SH, Hathaway WE. (eds.). Disorders of hemostasis & thrombosis. A clinical guide. 2nd ed. McGraw-Hill. NY. 2001; 501-504.
  11. Shapiro AD. Coagulation factors concentrates. In: Goodnight SH, Hathaway WE. (eds.). Disorders of hemostasis & thrombosis. A clinical guide. 2nd ed. McGraw-Yill Co. NY. 2001;505-516.
  12. Stehling L, Zauder HL. Fresh-Frozen Plasma: Indications for use. In: Spies BD, Counts RB, Gould SA. (eds.). Perioperative transfusion medicine. Williams&Wilkins. Baltimore etc. 1998;371-382.
  13. Levy JH, Morales A, Lemmer JH. Pyarmacological approaches to prevent or decrease bleeding in surgical patients. In: Spies BD, Counts RB, Gould SA. (eds.). Perioperative transfusion medicine. Williams&Wilkins. Baltimore etc. 1998;383-398.
  14. Zentai C, Grottke O, Spahn D, Rossaint R. Nonsurgical techniques to control massive bleeding. Anesth Clin. 2013;31:41-53. https://doi.org/10.1016/j.anclin.2012.10.005
  15. Weiskopf RB. Recombinant-activated coagulation factor VIIa (NovoSeven): current development. Vox Sang. 2007;92:281-288. https://doi.org/10.1111/j.14230410.2006.00888.x
  16. Franchini M, Lippi G. Recombinant activated factor VII: mechanisms of action and current indications. Semin Thromb Hemost. 2010;36:485-492. https://doi.org/10.1055/s-0030-1255442
  17. Hedner U, Kisiel W. Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors. J Clin Invest. 1983;71:1836-1841.
  18. Vdovin VV, Namestnikov YuA, Svirin PV, Galstyan GM. Trombin generation test for laboratory control therapy Glanzman trombasteny by Koagil - VII. Questions of hematology, oncology and immunopathology in pediatrics. 2010;3:41-44. (In Russ.)
  19. Zorenko VYu, Polyanskaya TYu, Galstjan GM, Vdovin VV. Experience of utilization of Koagil-VII during orthopedic surgery in patients with inhibitory hemophilia A. Questions of hematology, oncology and immunopathology in pediatrics. 2010;3:35-40. (In Russ.)
  20. Tarasova IS. Medical help for patients with inhibitory form of hemophilia. Questions of hematology, oncology and immunopathology in pediatrics. 2010;1:3-9. (In Russ.)
  21. Zorenko VYu, Galstyan GM, Polyanskaya TYu, Namestnikov YuA, Svirin PV. Comparison of hemostatic effect various preparates of recombinant activated hemostatic factor VII. Questions of hematology, oncology and immunopathology in pediatrics. 2011;4:16-22. (In Russ.)
  22. Logan AC, Yank V, Stafford RS. Off-label use of recombinant factor VIIa in United States hospitals: 2000—2008. Ann Intern Med. 2011;154:516-522. https://doi.org/10.7326/0003-4819-154-8-201104190-00002
  23. Yank V, Nuohy CV, Logan AC, Bravata DM, Staudenmayer K, Eisenhut R, Sundaram V, McMahon D, Olkin I, McDonald KM, Owens DK, Stafford RS. Comparative effectiveness review: Benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Intern Med. 2011;154:529-540. https://doi.org/10.7326/0003-4819-154-8-201104190-00004
  24. Scarpelini S, Rizoli S. Recombinant factor VIIa and the surgical patient. Curr Opin Crit Care. 2006;12:351-356. https://doi.org/10.1097/01.ccx.0000235214.6398854
  25. Warren OJ, Alcock EMH, Choong AMTL, Leff DR, Van Herzeele I, Darzi AW, Athanasiou T, Cheshire NJ. Recombinant activated factorVII: A solution to refractory haemorrhage in vascular surgery? Eur J Vasc Endovasc Surg. 2008;35:145-152. https://doi.org/10.1016/j.ejvs.2007.08.018
  26. Omar HR, Enten G, Karlnoski R, Ching YH, Mangar D, Camporesi EM. Recombinant activated factor VII significantly reduced transfusion requirements in cardiothoracic surgery. Drugs. 2015;15:187-194. https://doi.org/10.1007/s40268-015-093-9
  27. Schmid Р, Mordasini A, Luginbuhl M, Regli B, Kohler HP, Zimmermann H, Inderbitzin D, Hirt A, Lämmle B, Alberio L. Low-dose recombinant factor VIIa for massive bleeding. Swiss Medical Weekly (Europ J Med Sci). 2011;141:w13213. https://doi.org/10.4414/smw.2011.13213
  28. von Heymann C, Jonas S, Spies C, Wernecke KD, Ziemer S, Janssen D, Koscielny J. Recombinant activated factor VIIa for the treatment of bleeding in major abdominal surgery including vascular and urological surgery: a review and meta-analysis of published data. Crit Care. 2008;12:R14. https://doi.org/10.1186/cc6788
  29. Veldman A, Fischer D, Voight B, Beyer PA, Schlösser R, Allendorf A, Kreuz W. Life-treating hemorrhage in neonates: management with recombinant factor VII. Intensive Care Med. 2002;28:1635-1637. https://doi.org/10.1007/s00134-002-1489-x
  30. Rossaint R, Duranteau J, Stahel PF, Spahn DR. Nonsurgical treatment of major bleeding. Anesth Clin. 2007;25:35-48. https://doi.org/10.1016/j.anclin.2006.12.001
  31. De Gasperi A. Intraoperative use of recombinant activated factor VII (rVIIa). Minerva Anesthesiol. 2006;72:489-494.
  32. Sucker C, Sabel M, Stummer W, Zotz RB, Scharf RE, Gerhardt A. Recombinant factor VIIa for the prophylaxis of perioperative hemorrhage in a patient with congenital factor XI deficiency undergoing brain tumor neurosurgery. Clin Appl Thromb Hemost. 2008;14:472-475. https://doi.org/10.1177/1076029607305119
  33. Jones K, Greenberg R, Ahn ES, Kudchadkar SR. Elevated prothrombin time on routine preoperative laboratory results in a healthy infant undergoing craniosynostosis repair: Diagnosis and perioperative management of congenital factor VII deficiency. Int J Surg Case Rep. 2016;24:77-79. https://doi.org/10.1016/j.ijscr.2016.05.004
  34. Bay A, Aktekin E, Erkutlu I. A rare combination: congenital factor VII deficiency with Chiari malformation. Blood Coag Fibrinol. 2015;26:946-948. https://doi.org/10.1097/MBC0000000000000322
  35. Doran SE, Henry TR, Bockenstedt PL, Ross DA. Uncomplicated stereotactic and open neurosurgical procedures in patients with factor VII deficiency. Surg Neurol. 1994;42:79-82.
  36. Oymak Y, Muminogly N, Ay Y, Karapinar TH, Koker SA, Toret E, Yılmaz AK, Gurcınar М, Vergin С. Torticollis in a haemophylic infant with inhibitor: a case of spinal epidural hematoma. Blood Coag. Fibrinol. 2015;26:00-00. https://doi.org/10.1097/MBC.0000000000000465
  37. Liu N, Aldea S, Francois D, Cherqui-Michel M, Giansily-Blaizot M, Fischler M. Recombinant activated factor VII for a patient with factor VII deficiency undergoing urgent intracerebral haematoma evacuation with underlying cavernous angioma. Br J Anaesth. 2009;103:858-860. https://doi.org/10.1093/bja/aep293
  38. Rajpurkar M, Callaghan M, Frey MJ. Management of intracranial surgery for refractory epilepsy in severe factor VII deficiency: choosing the optimal dosing regimen. Haemophilia. 2014;20:e222-e224.
  39. Stein SC, Smith DH. Coagulopathy in traumatic brain injury. Neurocrit Care. 2004;1:479-488. https://doi.org/10.1385/NCC:1:4:479
  40. Sharma D, Vavilala MS. Perioperative management of adult traumatic brain injury. Anesthesiol Clin. 2012;30:333-346. https://doi.org/10.1016/j.anclin.2012.04.003
  41. Harhangi BS, Kompanje EJO, Leebeek EWG, Maas AIR. Coagulation disorders after traumatic brain injury. Acta Neurochir. 2008;150:165-175. https://doi.org/10.1007/s00701-007-1475-8
  42. Talvig P, Benfield R, Hadjazachara P. Coagulation in severe traumatic brain injury: a prospective study. J Trauma. 2009;66:55-62. https://doi.org/10.1097/TA.0b013e18190c3c0
  43. Zhang D, Gong S, Jin H, Wang J, Sheng P, Zou W, Dong Y, Hou L. Coagulation parameters and risk of progressive hemorrhagic injury after traumatic brain injury: a systematic review and metaanalysis. BioMed Res Internat. 2015. Article ID 261825. https://doi.org/10.1155/2015/261825
  44. Zhang J, Groff RF, Chen X-H, Browne KD, Huang J, Schwartz ED, Meaney DF, Johnson VE, Stein SC, Rojkjaer R, Smith DH. Hemostatic and neuroproyective effects of human recombinant activated factor VII theraphy after traumatic brain injury in pigs. Exp Neurol. 2008;210:645-655. https://doi.org/10.1016/j.expneurol.2007.12.019
  45. Yuan Q, Zhang D, Wu S, Yu J, Yu L, Sun Y, Du Z, Li Z, Zhou L, Wu X, Hu J. FVIIa prevents the progressive hemorrhaging of brain contusion by protecting microvessels via formation the TF-FVIIa-FXa complex. Neuroscience. 2017;348:114-125. https://doi.org/10.1016/neuroscience.2017.02.020
  46. Morensky JD, Tobias JD, Jimenez DF. Recombinant activated factor VII for cerebral injury-induced coagulopathy in pediatric patients. J Neurosurg. 2003;98:611-616. https://doi.org/10.3171/jns.2003.98.3.0611
  47. Park P, Fewel ME, Garton HJ, Thompson BG, Hoff JT. Recombunant activated factor VII for the rapid correction of coagulopathy in nonhemophilic neurosurgical patients. Neurosurgery. 2003;53:34-38.
  48. Perel P, Roberts I, Shakur H, Thinkhamrop В, Phuenpathom N, Yutthakasemsunt S. Haemostatic drugs for traumatic brain injury. Cochr Database Syst Rev. 2010;1:CD007877. https://doi.org/10.1002/14651858.CD007877.pub2
  49. Qiang Y, Wu X, Du Z-Y, Sun YR, Yu J, Li ZQ, Wu XH, Mao Y, Zhou LF, Hu J. Low-dose recombinant factor VIIa for reversing coagulopathy in patients with isolated traumatic brain injury. J Crit Care. 2015;30:116-120. https://doi.org/10.1016/j.jcrc.2014.07.009
  50. Nishijima DK, Offerman SR, Ballard DW, Vinson DR, Chettipally UK, Rauchwerger AS, Reed ME, Holmes JF. Clinical research in emergency services and treatment (CREST) networke risk of traumatic intracranial hemorrhage in patients with head injury and preinjury warfarin or clopidogrel use. Acad Emerg Med. 2013;20:140-145. https://doi.org/10.1111/acem.12074
  51. Goldberg R, Drummond KJ. Recombinant activated factor VII foe a warfarinised Jehovah’s witness with an acute subdural haemathoma. J Clin Neurosci. 2008;15:1164-1166. https://doi.org/10.1016/j.iocn.2007.05.030
  52. Juvela S, Kase CS. Advances in intracerebral hemorrhage management. Stroke. 2006;37:301-304. https://doi.org/10.1161/01.STR.0000200445.68303.25
  53. Flaherty ML, Woo D, Broderick JP. The epidemiology of intracerebral hemorrhage. In: Carhuapoma JR, Mayer SA, Hanley DF. (eds.). Intracerebral hemorrhage. Cambridge University press. NY. 2010;1-16.
  54. Aly AS, Kase CS. What should become the treatment of cerebral hemorrhage? In: Bogousslavsky J (ed.). Acute stroke treatment. 2nd ed. London: Martin Dunitz. 2003;195-207.
  55. Wijdicks EFM. Ganglionic and lobar hemorrhages. In: The clinical practice of critical care neurology. 2nd ed. Oxford university press. NY. 2003;221-240.
  56. Huang W-Y, Kruskall MS, Bauer KA, Uhl L, Shaz BH. The use of recombinant activated factor VII in three patients with central nervous system hemorrhages associated with factor VII deficiency. Transfusion. 2004;44:1562-1566. https://doi.org/10.1111/j.1537-2995.2004.04080.x
  57. Mendelow AD, Gregson BA, Fernandes HM, Murray GD, Teasdale GM, Hope DT, Karimi A, Shaw MD, Barer DH. STICH investigators early versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomized trial. Lancet. 2005;365:387-397. https://doi.org/10.1016/S0140-6736(05)17826-x
  58. Kumar S, Badrinath HR. Early recombinant factor VIIa in acute intracerebral hemorrhage. Neurol India. 2006;54:24-27.
  59. Guan J, Hawryluk WJ. Targeting secondary hematoma e[pansion in spontaneous intracerebral hemorrhage — State of the art. Front Neurol. 2016;7Article 187. https://doi.org/10.3389/fneur.2016.00187
  60. Greenberg SM. Cerebral amyloid angiopathy. In: Carhuapoma JR, Mayer SA, Hanley DF. (eds.). Intracerebral hemorrhage. Cambridge Univ Press. NY. 2010;41-57.
  61. Naval NS, Nyquist PA, Carhuapoma JR. Medical management of intracerebral hemorrhage. In: Carhuapoma JR, Mayer SA, Hanley DF. (eds.). Intracerebral hemorrhage. Cambridge University press. NY. 2010;159-164.
  62. Mendelow AD. Surgical management of intracerebral hemorrhage. In: Carhuapoma JR, Mayer SA, Hanley DF. (eds.). Intracerebral hemorrhage. Cambridge University press. NY. 2010;165-175.
  63. Nyquist PA, Naval NS, Carhuapoma JR. Future therapy in intracerebral and intraventricular hemorrhage: aspiration and thrombolysis. In: Carhuapoma JR, Mayer SA, Hanley DF. (eds.). Intracerebral hemorrhage. Cambridge University press. NY. 2010;176-186.
  64. Xi G, Keep RF, Hoff JT. Thrombin and secondary brain damage following intracerebral hemorrhage. In: Carhuapoma JR, Mayer SA, Hanley DF. (eds.). Intracerebral hemorrhage. Cambridge University press. NY. 2010;206-216.
  65. Ziai WC, Mayer SA. Hemostatic therapy for intracerebral hemorrhage. In: Carhuapoma JR, Mayer SA, Hanley DF. (eds.). Intracerebral hemorrhage. Cambridge University press. NY. 2010;238-253.
  66. Brody DL, Aiyagari V, Shakleford AM, Diringer MN. Use of recombinant VIIa in patients with warfarin-associated hemorrhage. Neurocrit Care. 2005;2:263-267. https://doi.org/10.1385/NCC:2:3:263
  67. You H, Al-Shahi Salman R. Hemostatic drug therapies for acute primary intracerebral haemorrhage. Cochraine Syst Rev. 2006;Iss. 3:Art. No: CD005951. https://doi.org/10.1002/14651858.CD005951.pub2
  68. Yuan ZH, Jiang JK, Huang WD, Pan J, Zhu JY, Wang JZ. A metaanalysis of the efficacy and safety of recombinant activated factor VII for patients with acute intracerebral hemorrhage without hemophilia. J Clin Neurosci. 2010;17:685-693. https://doi.org/10.1016/j.jocn.2009.11.020
  69. Steiner T, Bosel J. Options to restrict hematoma expansion after spontaneous intracerebral hemorrhage. Stroke. 2010;41:402-409. https://doi.org/10.1161/STROKEAHA.109.552919
  70. Solari D, Cavallo LM. Intracranial hemorrhage: How to return from warfarin effect. World Neurosurg. 2014;81:40-42. https://doi.org/10.1016/j.wneu.2013.01.121
  71. Mayer SA, Davis SM, Skolnik BE, Brun NC, Begtrup K, Broderick JP, Diringer MN, Steiner T. FAST trial investigator. Can a subset of intracerebral hemorrhage patients benefit from hemostatic therapy with recombinant activated factor VII? Stroke. 2009;40:833-840. https://doi.org/10.1161/STROKEAHA.108.524470
  72. Fewel ME, Park P. The emerging role of recombinant-activated factor VII in neurocritical care. Neurocrit Care. 2004;1:19-29. https://doi.org/10.1385/NCC:1:1:19
  73. Yampolsky N, Stofko D, Veznedaroglu E, Liebman K, Binning MJ. Recombinant factor VIIa use in patients presenting with intracranial hemorrhage. Springer Plus. 2014;3:471(1-5). https://doi.org/10.1186/2193-1801-2-471
  74. Steiner T, Diringer MN, Schneider D, Mayer SA, Begtrup K, Broderick J, Skolnick BE, Davis SM. Dynamics of intraventricular hemorrhage in patients with spontaneous intracerebral hemorrhage: risk factors, clinical impact, and effect of hemostatic therapy with recombinant activated factor VII. Neurosurgery. 2006;59:767-774. https://doi.org/10.1227/01.NEU.0000232837.34992.32
  75. Pickard JD, Kirkpatrick PJ, Melsen T. Potential role of Novoseven in prevention of rebleeding following aneurismal subarachnoid hemorrhage. Blood Coag Fibrinol. 2000;11(Suppl. 12):S117-S120.
  76. Gerlach R, Marquardt G, Wissing H, Scharrer I, Raabe A, Seifert V. Application of recombinant factor VII during surgery for a giant skull base hemangiopericitoma to achieve safe hemostasis. Case report. J Neurosurg. 2002;96:946-948. https://doi.org/10.3171/jns.2002.96.5.0946
  77. Kapapa T, Konig K, Heissler H, Schatzmann C, Tschan CA, Perl M, von Depka M, Zumkeller M, Rickels E. The use of recombinant activated factor VII in neurosurgery. Surg Neurol. 2009;71:172-179. https://doi.org/10.1016/j.surneu.2007.07.048
  78. Felfernig M, Huepfl M. Experience of recombinant activated factor VII (NovoSeven) in the operating theatre and intensive care unit for the management of intracranial bleeding in nonhaemophilic patients. Clin Neurol Neurosurg. 2008;110:227-232. https://doi.org/10.1016/j.clineuro.2007.10.019
  79. McClelland SIII, Won EK, Lam CH. Utilization of recombinant activated factor VII for intracranial hematoma evacuation in coagulopathis nonhemophilic neurosurgical patients with normal international normalized ratios. Neurocrit Care. 2007;7:136-139. https://doi.org/10.1007/s12028-007-0040-x
  80. Uhrig L, Blanot S, Baugnon T, Orliaguet G, Carli PA, Meyer PG. Use of recombinant activated factor VII in intractable bleeding during pediatric neurosurgical procedures. Pediatr Crit Care Med. 2008;8:576-579. https://doi.org/10.1097/01.PCC.0000282734.17597.00
  81. Hartmann M, Sucker C, Messing M. Recombinant activated factor VII in the treatment of near-fatal bleeding during pediatric brain tumor surgery. Report of two cases and review of the literature. J Neurosurg;1 Suppl. Pediatrics. 2006;104:55-58. https://doi.org/10.371/ped.2006.104.1.55
  82. Lemeneva NV, Sorokin VS, Lubnin AYu. Blood saving methods in pediatric neuroanesthesiology. Anesth. and Rean. 2008;2:22-26. (In Russ.)
  83. Lemeneva NV. Therapy and prophylaxis of massive blood loss during neurosurgical procedures in pediatric patients: Dissertaton of kand. med. sci. Moscow. 2008;144. (In Russ.)
  84. Matuev KB, Gorelishev SK, Lubnin AYu, Sorokin VS, Lemeneva NV. Blood loss during surgery of cerebral tumors in children’s of first year of life. Journ Voprosi Neurochir. 2013;4:3-15. (In Russ.)
  85. Willner D, Spennati V, Stohl S, Tosti G, Aloisio S, Bilotta F. Spine surgery and blood loss: systematic review of clinical evidence. Anesth Analg. 2016;123:1-9. https://doi.org/10.1213/ANE.0000000000001485
  86. Weiskopf RB. The use of recombinant activated coagulation factor VII for spine surgery. Eur Spine J. 2004;13:Suppl. 1:S83-S88.
  87. Levi M, Levy JH, Friis Andersen H, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med. 2010;363:1791-1800. https://doi.org/10.1056/NEJMoa1006221
  88. H-Y CS, Xuemei C, G KR, M BL, V HG, A SF, K FS. Thromboembolic risks of recombinant factor VIIa use in warfarin-associated intracranial hemorrhage: a case-control study. BMC Neurol. 2012;12:158-165. https://doi.org/10.1186/1471-2377-12-158
  89. Hartmann M, Sucker C. Pharmacology and clinical use of recombinant activated factor seven in neuroscience. Neurocrit Care. 2007;6:149-157. https://doi.org/10.1007/s12028-007-0006-z
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.